Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S29-S39 , 20 December 2007

PPARγ agonists—Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes

References 

  1. Bailey CJ. The rise and fall of troglitazone. Diab. Med. 2000;17:414–415
  2. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials. Evidence that rosiglitazone does not cause hepatic dysfunction. Diab. Care. 2002;25:815–821
  3. Wagstaff AJ, Goa KL. Rosiglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs. 2002;62:1805–1837
  4. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes. Drugs. 2006;66:85–109(Erratum: Drugs 66 (2006) 340–341)
  5. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003;63:1373–1405
  6. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur. J. Intern. Med. 2007;18:18–25
  7. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000;43:527–550
  8. Jermendy G, Csermely P. Thiazolidinediones—a new class of oral antidiabetic drugs. Orv. Hetil. 2001;142:1547–1554
  9. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann. Med. 2002;34:217–224
  10. Lowell BB. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 1999;99:239–242
  11. Hauner H. The mode of action of thiazolidinediones. Diab. Metab. Res. Rev. 2002;18(Suppl. 2):S10–S15
  12. Goldberg RB. Impact of thiazolidenediones on serum lipoprotein levels. Curr. Atheroscler. Rep. 2006;8:397–404
  13. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diab. Care. 1999;22:908–912
  14. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diab. Care. 2000;23:1067–1071
  15. Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, Takahashi M, et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation—double-blind placebo-controlled trial. Diab. Res. Clin. Pract. 2001;54:181–190
  16. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J. Clin. Endocrinol. Metab. 2006;91:3553–3558
  17. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968–2974
  18. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J. Hypertens. 2006;24:2047–2055
  19. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effect of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diab. Care. 2002;25:2058–2064
  20. Sarafidis PA, Nilsson PM. The effects of thiazolidinediones on blood pressure levels—a systematic review. Blood Press. 2006;15:135–150
  21. Martens FMAC, Visseren FLJ, Lemay J, Koning de EJP, Rabelink TJ. Metabolic and additional vascular effects of thiazolodinediones. Drugs. 2002;62:1463–1480
  22. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  23. Ishibashi M, Egashira K, Hiasa K, Onoue S, Ni W, Zhao Q. Antiinflammatory and antiatherosclerotic effects of pioglitazone. Hypertension. 2002;40:687–693
  24. Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J. Int. Med. Res. 2006;34:545–555
  25. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, et al. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2003;23:283–288
  26. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diab. Care. 2004;27:1349–1357
  27. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol. 2005;25:1804–1809
  28. Pfutzner A, Hohberg C, Lubben G, Pahler S, Pfutzner AH, Kann P, et al. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm. Metab. Res. 2005;37:510–515
  29. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50:1021–1029
  30. Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs. 2005;65:1–13
  31. Pershadsingh HA. Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis?. Exp. Opin. Invest. Drugs. 2004;13:215–228
  32. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2001;86:280–288
  33. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diab. Care. 2005;28:1547–1554
  34. Kendall DM. Thiazolidinediones. The case for early use. Diab. Care. 2006;29:154–157
  35. Tang WH, Fracis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. JACC. 2003;41:1394–1398
  36. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–2948
  37. Pavo I, Jermendy G, Varkonyi T, Kerenyi Z, Gyimesi A, Shoustov S, et al. Effect of pioglitazone compared with metformin on glycemic control and indications of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003;88:1637–1645
  38. The ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006;355:2427–2443
  39. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711–1721(Erratum: Diabetologia 49 (2006) 2816–2818)
  40. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA. 2000;283:1695–1702
  41. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diab. Obes. Metab. 2003;5:163–170
  42. Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diab. Med. 2000;17:40–47
  43. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr. Pract. 2002;8:271–275
  44. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diab. Care. 2006;29:554–559
  45. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–2803
  46. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517–522
  47. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150–1156
  48. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–1105
  49. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 2001;86:3452–3456
  50. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572–2581
  51. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2004;24:930–934
  52. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diab. Care. 2004;27:2654–2660
  53. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diab. Care. 2006;29:101–106
  54. The PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  55. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet. 2005;366:1241–1242
  56. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2006;4:CD006060
  57. Erdmann E, Charbonnel B, Dormandy J, Massi-Benedetti M, Skene A, Wilcox R, et al. Pioglitazone treatment in patients with type 2 diabetes and a history of myocardial infarction: subgroup analyses from PROactive stratified by gender, age, and duration of diabetes. Diabetologia. 2006;49(Suppl. 1):755;(abstract)
  58. Wilcox R, Bousser MG, Dormandy J, Perez A. Effect of pioglitazone in stroke prevention in type 2 diabetes: a prespecified subgroup analysis of PROactive. Diabetes. 2006;55(Suppl. 1):A138;(abstract)
  59. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia. 2005;48:1726–1735
  60. Macfarlane DP, Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure. Am. J. Cardiovasc. Drugs. 2006;6:297–304
  61. Ratziu V, Jacqueminer S, Giral P, Podevin P, Serfaty L, Charlotte F, et al. A one-year, randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: results of the FLIRT pilot trial. Diabetologia. 2006;49(Suppl. 1):755;(abstract)
  62. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951–953
  63. Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy. 2005;25:244–252
  64. Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM. Treatment of psoriasis with troglitazone therapy. Arch. Dermatol. 1998;134:1304–1305
  65. Robertshaw H, Friedmann PS. Pioglitazone: a promising new therapy for psoriasis. Br. J. Dermatol. 2005;152:189–191
  66. Shafig N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K. Pioglitazone versus placebo in patients with plaque psoriasis. Int. J. Dermatol. 2005;44:328–333
  67. Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm. Venereol. 2005;85:194–202
  68. Hashimoto Y, Nakahara K. Improvement of asthma after administration of pioglitazone. Diab. Care. 2002;25:401
  69. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, et al. An open-label trial of the PPARγ-ligand rosiglitazone for active ulcerative colitis. Am. J. Gastroenterol. 2001;96:3323–3328
  70. Wohl DA. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV infection and its therapies. Top. HIV Med. 2004;12:89–93
  71. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy?. Curr. Med. Chem. Anticancer Agents. 2004;4:465–477
  72. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17:27–45
  73. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry. 2005;13:950–958

PII: S0168-8227(07)00496-2

doi: 10.1016/j.diabres.2007.09.017

Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S29-S39 , 20 December 2007

Article Tools

* Image Usage & Resolution